Bristol Myers Squibb and partner Pfizer won a key patent decision after a federal judge in the US ruled in favour of the companies in a dispute over Eliquis, reported MarketWatch.
The judge said that products made by Sigmapharm Laboratories, Sunshine Lake Pharma Co., and Unichem Laboratories infringed patents protecting the anticoagulant, which is generically known as apixaban.
"While subject to appeal, at present the generic manufacturers currently involved in the case cannot launch their apixaban products until 2031," said a Bristol Myers Squibb spokewoman.
She added that "based on settlement agreements reached with other generic manufacturers, we currently expect generic entry could occur after 2026 but before 2031, subject to appeals and future challenges."
Bristol Myers Squibb and Pfizer have a profit-sharing agreement on the drug, which generated $2 billion last year.
To read more NewsPoints articles, click here.